Showing results (271-280 of 293) with videos related to

Sort By:
Pageof 30
Liver Cancer|July 9, 2026
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort StudyTeng-Yu Lee, Pei-Chang Lee, Ying-Chun Shen, et al.
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Hepatology Communications|January 13, 2021
Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular CarcinomaVincent L Chen, Ming-Lun Yeh, Ju Dong Yang, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|December 31, 2022
Recommendations and guidelines for the diagnosis and management of Coronavirus Disease-19 (COVID-19) associated bacterial and fungal infections in TaiwanHuan-Yi Wu, Peng-Hao Chang, Yu-Shan Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular CarcinomaDaniel Q Huang, Joseph K Hoang, Rubayet Kamal, et al.
The Lancet. Infectious Diseases|October 9, 2025
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trialDavid L Paterson, Helmi Sulaiman, Po-Yu Liu, et al.
Hepatology International|December 5, 2020
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohortYasuhito Tanaka, Eiichi Ogawa, Chung-Feng Huang, et al.
Hepatology International|August 30, 2019
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C ConsortiumChung-Feng Huang, Etsuko Iio, Dae Won Jun, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2019
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice ImplicationEiichi Ogawa, Hidenori Toyoda, Etsuko Iio, et al.
Alimentary Pharmacology & Therapeutics|January 4, 2024
Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic responseJung Eun Park, Vy H Nguyen, Pei-Chien Tsai, et al.
Pageof 30